



**U.S. Food and Drug Administration**  
Protecting and Promoting Public Health

[www.fda.gov](http://www.fda.gov)

# **Medical Device Inspections**

**FDA Small Business  
Regulatory Education for Industry (REdI)  
Bethesda, MD  
September 26, 2013**

**Lori S. Lawless**

Supervisory Consumer Safety Officer  
Baltimore District Office  
Office of Regulatory Affairs  
U.S. Food and Drug Administration



# Office of Regulatory Affairs

- The Office of Regulatory Affairs (ORA) is the lead office for all field activities at the FDA.
- Regulating more than **135,000 business establishments** that annually produce, warehouse, import and transport **\$1 trillion** worth of consumer goods.


# Investigators

## Part of the Office of Regulatory Affairs

- More than 4,400 ORA personnel in more than 200 locations work everyday to maximize compliance of regulated products and to minimize public health risk
- Office of Criminal Investigations (OCI)

# Office of Regulatory Affairs

## Field Operations: Regional/District Offices



# Investigators

- Also known as a Consumer Safety Officer.
- Have a science background.
- Work in Food, Devices, Drugs, BIMO, Blood & Biologics, and Imports.
- Receive training according to discipline.
- May be part of international inspection Cadre

# How does FDA decide who to inspect?

- Registration database identifies who manufacturers devices for distribution in the U.S.
- Listing database identifies what devices they distribute
- FDA prioritizes inspections by risk and gives higher risk devices/situations a higher priority

# How does FDA choose ?

- Mandated by law, every 2 years for class II and class III device manufacturers
- Risk
- Follow up inspections to a regulatory action
- Complaints (public & industry)



# Investigator Tools

- Federal Food, Drug, and Cosmetic Act
- 21 Code of Federal Regulations (800-1299)
- Quality Systems Manual: A Small Entity Compliance Guide on-line



# Investigator Tools

- Compliance Policy Guides
- Quality System Inspection Techniques (QSIT)
- Compliance Program Guidance Manual
- CP 7382.845 Inspection of Medical Device Manufacturers available on-line

# Investigator Tools

- **Investigations Operations Manual**
  - 5.2.1.1 Preannouncements
  - 5.6.2 Medical Device Quality System/ GMP
  - 5.6.9 Device Inspection Reports
  - 5.10.4.3.9 Manufacturing/Design Operations
    - Specific Instructions for medical device EIRs
  - 5.10.4.3.16 Additional information
    - Specific Instructions for medical device EIRs

# Investigator Tools

- Previous Establishment Inspections Reports
- Training Courses
- Other investigators or FDA Labs
- DSMICA



# Investigator Tools

- Guidance Documents (can be accessed from [www.FDA.gov](http://www.FDA.gov) website under Medical devices CDRH Device Advice)
- Internet
- Other Federal, State and Local agencies
- FDA Recognized Consensus Standards

# **What is high priority for an inspection?**

- Make Class III or Class II devices
- Make implantable devices and life supporting and life sustaining devices
- Recently introduced a new device to the market
- Have had significant violations and complaints in the past

# **Does FDA notify the manufacturer of an upcoming inspection?**

- FDA calls domestic manufacturers up to 5 calendar days before the inspection
- FDA contacts foreign manufacturers 2 - 3 months in advance to schedule inspection
- Manufacturer may be requested to send Quality System Manual or equivalent for pre-inspection review

# **What happens when the FDA investigator arrives at the site?**

- Ask to see the top management (“most responsible person” at the firm.
- Present credentials (identification as an authorized FDA investigator)
- Issue FDA-482 “Notice of Inspection” (explains FDA’s legal authority to inspect)



## This is an example of Form FDA 482, Notice of Inspection

<b>DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION</b>		1. DISTRICT OFFICE ADDRESS & PHONE NO.	
2. NAME AND TITLE OF INDIVIDUAL		3. DATE	
4. FIRM NAME		5. HOUR a.m. p.m.	
6. NUMBER AND STREET			
7. CITY AND STATE & ZIP CODE		8. PHONE NO. & AREA CODE	
<b>Notice of Inspection is hereby given pursuant to Section 704(a)(1) of the Federal Food, Drug, and Cosmetics Act [21 U.S.C. 374(a)]<sup>1</sup> and/or Part F or G, Title III of the Public Health Service Act [42 U.S.C. 262-264]<sup>2</sup></b>			
<p>As a small business that is subject to FDA regulation, you have the right to seek assistance from the U.S. Small Business Administration (SBA). This assistance includes a mechanism to address the enforcement actions of Federal agencies. SBA has a National Ombudsman's Office that receives comments from small businesses about Federal agency enforcement actions. If you wish to comment on the enforcement actions of FDA, CALL (888) 734-3247. The website address is <a href="http://www.sba.gov/ombudsman">www.sba.gov/ombudsman</a>.</p> <p>FDA has an Office of the Ombudsman that can directly assist small business with complaints or disputes about actions of the FDA. That office can be reached by calling (301) 796-8530 or by email at <a href="mailto:ombuds@oc.fda.gov">ombuds@oc.fda.gov</a>.</p> <p>For industry information, go to <a href="http://www.fda.gov/oc/industry">www.fda.gov/oc/industry</a>.</p>			
9. SIGNATURE(S) (Food and Drug Administration Employee(s))		10. TYPE OR PRINT NAME(S) AND TITLE(S) (FDA Employee(s))	
<sup>1</sup> Applicable portions of Section 704 and other Sections of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 374] are quoted below:		described in section 414, when the standard for records inspection under paragraph (1) or (2) of section 414(a) applies, subject to the limitations established in section 414(d). In the case of any factory, warehouse, establishment, or consulting laboratory in which prescription drugs, nonprescription drugs intended for human use, restricted devices, or tobacco products are manufactured, processed, packed, or held, inspection shall extend to all things therein (including records, files, papers, processes, controls, and facilities) bearing on whether prescription drugs, nonprescription drugs intended for human use, restricted devices, or tobacco products which are adulterated or misbranded within the meaning of this Act, or which may not be manufactured, introduced into interstate commerce, or sold, or offered for sale by reason of any provision of this Act, have been or are being manufactured, processed, packed, transported, or held in any such place, or otherwise bearing on violation of this Act. No inspection authorized by the preceding sentence or by paragraph (3) shall extend to financial data, sales data other than shipment data, pricing data, personnel data (other than data as to qualifications of technical and professional personnel performing functions subject to this	
Sec. 704(a)(1) For purposes of enforcement of this Act, officers or employees duly designated by the Secretary, upon presenting appropriate credentials and a written notice to the owner, operator, or agent in charge, are authorized (A) to enter, at reasonable times, any factory, warehouse, or establishment in which food, drugs, devices, tobacco products, or cosmetics are manufactured, processed, packed, or held, for introduction into interstate commerce or after such introduction, or to enter any vehicle being used to transport or hold such food, drugs, devices, tobacco products, or cosmetics in interstate commerce; and (B) to inspect, at reasonable times and within reasonable limits and in a reasonable manner, such factory, warehouse, establishment, or vehicle and all pertinent equipment, finished and unfinished materials, containers, and labeling therein. In the case of any person (excluding farms and restaurants) who manufactures, processes, packs, transports, distributes, holds, or imports foods, the inspection shall extend to all records and other information		(Continued on Reverse)	

# Can you refuse an inspection?

- Under section 704 of the FD&C Act, FDA is authorized to enter establishments.
- They are further authorized to inspect “at reasonable times and within reasonable limits and in a reasonable manner”.
- FDA can also seek an Administrative Inspection Warrant from a United States District Court.

# What happens next?

- Gather information about size and structure of company, who are the responsible officials, what products are manufactured there.
- Evaluate the manufacturer's Quality System using the Quality System Inspection Technique (QSIT)

# What happens during the inspection?

- Investigator may tour the facility to get an idea of layout, workflow, and areas that may need closer inspection. (Start Big, Get Small)
- This helps the investigator decide how to organize the inspection

# What happens during the inspection?


- The Investigator may request to interview employees, take samples (484 Receipt for Sample) and make copies of documents.
- The Investigator may also request to take pictures during the inspection

# What is QSIT?


- Identifies 4 major subsystems to evaluate and states the purpose and importance of each subsystem
- Provides flowcharts and inspectional objectives to cover during inspection
- Offers advice on inspection
- Provides tables for statistical sampling of records for review

# What is QSIT?

- <http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074883.htm>



# Subsystems of the Quality System



# Does FDA conduct different types of inspections?

- Investigator may conduct 1 of 4 types of inspections for medical devices:
  - Level 1 – Abbreviated QSIT
  - Level 2 – Baseline QSIT (Comprehensive)
  - Compliance follow-up
  - “For Cause”

# **What is a Level 2 baseline (comprehensive) inspection?**

- Covers all 4 main subsystems
- Is conducted when the firm has never had Level 2 inspection and every 6 years thereafter, resources permitting
- Provides an overall evaluation of the firm's quality system

# What is a Level 1 abbreviated inspection?

- Is conducted after firm has had a Level 2 inspection, and quality system was in compliance with requirements
- Covers CAPA plus one other major subsystem
- Covers a different subsystem each time

# What is a “For Cause” Inspection?

- Initiated at the request of CDRH, ORA Headquarters, Regional or District Directive
- Dictated by the source of information and may differ from typical QSIT approach
- These inspections are generally more in depth in particular areas than typical QSIT inspections
- Conducted as the need arises
  - Important note in CP, if the Investigator encounters a serious public health risk during the QSIT inspection the investigator may switch to a for cause inspection

# **What is a compliance follow-up inspection?**

- Is conducted to verify adequate correction of previous violations or document continuing violations to support possible regulatory action
- Is conducted to follow up on information indicating serious problems at firm
- May include elements of QSIT

# What happens at the end of the inspection?

- Meet with management to discuss the inspection
- Present the FDA 483 “List of Observations” of any significant observations
- Discuss the observations



This is an example of the FDA Form 483, Inspectional Observations.

The header identifies the FDA district office that performed the inspection, the date(s) of inspection, name and address of the facility that was inspected, the name and title of the individual to whom the 483 is issued to (usually the most responsible individual physically present in the facility), a brief description of the type of facility, and the facility's FEI (FDA Establishment Identification) number.

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION			
DISTRICT OFFICE ADDRESS AND PHONE NUMBER		DATE(S) OF INSPECTION	
		FEI NUMBER	
Industry Information: <a href="http://www.fda.gov/oc/industry">www.fda.gov/oc/industry</a>			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED			
TO:			
FIRM NAME		STREET ADDRESS	
CITY, STATE AND ZIP CODE		TYPE OF ESTABLISHMENT INSPECTED	
<small>THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.</small>			
<small>The observations noted in this Form FDA 483 are not an exhaustive listing of objectionable conditions. Under the law, your firm is responsible for conducting internal self-audits to identify and correct any and all violations of the quality system requirements.</small>			
DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:			
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE (Print or Type)	DATE ISSUED



# FDA-483 “Inspectional Observations”

- The content of a 483 may be handwritten, typed, completed in a PDF file and printed, or completed via the FDA's computer system called **Turbo EIR**.
- The observations listed on this form do not represent a final agency determination regarding your compliance. An additional statement only included for medical devices is that the observations are not an exhaustive listing of objectionable conditions. Under law your firm is responsible for conducting internal self-audits to identify and correct any and all violations of the quality system requirements.”
- If the firm has promised and/or completed a corrective action to an FDA 483 prior to the completion of the inspection, the FDA 483 should be annotated.

# FDA-483 “Inspectional Observations”

## •Turbo EIR?

- Links citations to underlying regulations and statutes
- Provides uniform FDA-483s and EIRs
- Improves data analysis



# What are annotations to the 483?

As of 1997, the FDA established an annotation policy for medical device inspections. The investigator(s) should offer to annotate the 483 with one or more of the following:

- *Reported corrected, not verified*
- *Corrected and verified*
- *Promised to correct*
- *Under consideration*

The actual annotation of the 483 occurs during the final discussion with the firm's management; if the firm prefers no annotation, then annotation will not be performed. The annotations may be after each observation, at the end of each page, or at the bottom of the last page prior to the investigator's signature(s).

The term “verified” means “to confirm; to establish the truth or accuracy”. In this case, the investigator must do the verification. In some situations, they will not be able to verify the corrective action unless there is further district or Center review or until there is another inspection of the establishment. If the firm has promised correction and furnishes a date or timeframe for completion, this may be added to the annotation. If the investigator and firm have “agreed to disagree” about the validity of an observation, the observation may be annotated with “under consideration” or no annotation is used, based on the firm’s decision.



# Top 10 Devices Observations Used in Turbo EIR

Cite ID	Count	Reference No.	Citation Text
3130	1686	21 CFR 820.100(a)	Procedures for corrective and preventive action have not been [adequately] established. Specifically, ***
630	1179	21 CFR 803.17	Written MDR procedures have not been [developed] [maintained] [implemented]. Specifically, ***
4189	1093	21 CFR 820.198(a)	Complaint handling procedures for [receiving] [reviewing] [evaluating] complaints have not been [established] [defined] [documented] [completed] [implemented]. Specifically, ***
3696	1074	21 CFR 820.100(b)	Corrective and preventive action activities and/or results have not been [adequately] documented. Specifically, ***
546	975	21 CFR 820.75(a)	A process whose results cannot be fully verified by subsequent inspection and test has not been [adequately] validated according to established procedures. Specifically, ***
3415	833	21 CFR 820.22	Quality [audits][reaudits] have not been performed. Specifically, ***
2327	786	21 CFR 820.22	Procedures for quality audits have not been [adequately] established. Specifically, ***
2371	704	21 CFR 820.30(a)	Procedures for design control have not been established. Specifically, ***
3103	692	21 CFR 820.30(i)	Procedures for design change have not been [adequately] established. Specifically, ***
479	658	21 CFR 820.50	Procedures to ensure that all purchased or otherwise received product and services conform to specified requirements have not been [adequately] established. Specifically, ***

# **What should the manufacturer do after the inspection?**

- Send a letter to FDA identifying how they have corrected observations or will correct them
- Provide documentation of any corrections that have been completed
- Provide a timetable or estimated completion date for future corrections

# What happens next?

- Investigator returns to office to write an “Establishment Inspection Report” or EIR
- Inspection is classified based on inspectional findings
- Compliance officer decides whether to recommend regulatory action

# How does FDA classify inspection reports?

- NAI – No action indicated
- VAI – Voluntary action indicated – some deficiencies identified but not serious
- OAI – Official action indicated – serious deficiencies identified, and FDA must take action to assure correction

# **What actions can FDA take to address OAI inspections?**

- Warning Letter
- Seizure
- Injunction
- Civil penalties
- Criminal

# Warning Letter

- FDA sends “Warning Letter” describing manufacturer’s violations of FDA regulations and requesting a reply within 15 days
- FDA inspects the manufacturer 6 - 12 months after sending the Warning Letter to confirm correction of deficiencies

# Providing Industry Education and Assistance – CDRH Resources

- **CDRH Learn – Online Regulatory Training Tool**
  - Over 50 Medical device and Radiological Health modules
  - Video and PowerPoint presentations available 24/7
  - Certificate of completion upon passing post-tests
  - Many modules are translated into Chinese and Spanish
  - <http://www.fda.gov/Training/CDRHLearn/>
- **Device Advice – Online Regulatory Information**
  - Searchable by topic
  - <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/>
  - [dsmica@fda.hhs.gov](mailto:dsmica@fda.hhs.gov)



# Providing Industry Education and Assistance – CDRH Resources

## CDRH Learn – Regulatory Topics

- Overview of Regulatory Requirements: Medical Devices
- Guidance Documents and Standard Operating Procedures (SOPs)
- Premarket Notification Process - 510(k)
- Investigational Device Exemption Process – IDE
- Bioresearch Monitoring (BIMO)
- Device Establishment Registration and Listing
- CDRH Regulated Software: An Introduction
- Quality System Regulation 21 CFR Part 820
- Medical Device Recalls
- Medical Device Reporting (MDR)
- Export Certificates for Medical Devices
- Regulation of Radiation-Emitting Products
- Global Initiatives
- Medical Devices In the Home
- Unique Device Identification (UDI) System